Literature DB >> 9665469

Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor.

J A Uría1, M Balbín, J M López, J Alvarez, F Vizoso, M Takigawa, C López-Otín.   

Abstract

Human collagenase-3 (MMP-13) is a member of the matrix metalloproteinase family of enzymes that was originally identified in breast carcinomas and subsequently detected during fetal ossification and in arthritic processes. In this work, we have found that collagenase-3 is produced by HCS-2/8 human chondrosarcoma cells. An analysis of the ability of different cytokines and growth factors to induce the expression of collagenase-3 in these cells revealed that basic fibroblast growth factor (bFGF or FGF-2) strongly up-regulated the expression of this gene. By contrast, other factors, including interleukin-1beta and transforming growth factor-beta, previously found to induce collagenase-3 expression in other cell types, did not exhibit any effect on the expression of this gene in chondrosarcoma cells. Further analysis of the bFGF-induced expression of collagenase-3 in human chondrosarcoma cells revealed that its effect was time and dose dependent, but independent of the de novo synthesis of proteins. Western blot analysis revealed that the up-regulatory effect of bFGF on collagenase-3 was also reflected at the protein level as demonstrated by the increase of immunoreactive protein in the conditioned medium of HCS-2/8 cells treated with bFGF. Immunohistochemical analysis of the presence of collagenase-3 in a series of 8 benign and 16 malignant cartilage-forming neoplasms revealed that all analyzed malignant chondrosarcomas stained positively for collagenase-3, whereas only 2 of 8 benign lesions produced this protease. In addition, the finding that bFGF was detected in all analyzed chondrosarcomas, together with the above in vitro studies on HCS-2/8 cells, suggest that this growth factor may be an in vivo modulator of collagenase-3 expression in these malignant tumors. These results extend the pattern of tumor types with ability to produce this matrix metalloproteinase and suggest that collagenase-3 upregulation may contribute to the progression of human chondrosarcomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665469      PMCID: PMC1852961          DOI: 10.1016/S0002-9440(10)65549-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  52 in total

1.  Collagenase 3 (matrix metalloproteinase 13) gene expression by HaCaT keratinocytes is enhanced by tumor necrosis factor alpha and transforming growth factor beta.

Authors:  N Johansson; J Westermarck; S Leppä; L Häkkinen; L Koivisto; C López-Otín; J Peltonen; J Heino; V M Kähäri
Journal:  Cell Growth Differ       Date:  1997-02

2.  Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival.

Authors:  D M Nanus; B J Schmitz-Dräger; R J Motzer; A C Lee; V Vlamis; C Cordon-Cardo; A P Albino; V E Reuter
Journal:  J Natl Cancer Inst       Date:  1993-10-06       Impact factor: 13.506

Review 3.  Tumor cell interactions with the extracellular matrix during invasion and metastasis.

Authors:  W G Stetler-Stevenson; S Aznavoorian; L A Liotta
Journal:  Annu Rev Cell Biol       Date:  1993

4.  Collagenase-3 (MMP-13) is expressed by hypertrophic chondrocytes, periosteal cells, and osteoblasts during human fetal bone development.

Authors:  N Johansson; U Saarialho-Kere; K Airola; R Herva; L Nissinen; J Westermarck; E Vuorio; J Heino; V M Kähäri
Journal:  Dev Dyn       Date:  1997-03       Impact factor: 3.780

5.  Regulation of interstitial collagenase expression and collagen degradation by retinoic acid in bone cells.

Authors:  S Varghese; S Rydziel; J J Jeffrey; E Canalis
Journal:  Endocrinology       Date:  1994-06       Impact factor: 4.736

6.  Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action.

Authors:  L I Gold; B Saxena; K R Mittal; M Marmor; S Goswami; L Nactigal; M Korc; R I Demopoulos
Journal:  Cancer Res       Date:  1994-05-01       Impact factor: 12.701

7.  Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage.

Authors:  Y Yamanaka; H Friess; M Buchler; H G Beger; E Uchida; M Onda; M S Kobrin; M Korc
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

8.  Basic fibroblast growth factor in human prostate cancer cells.

Authors:  T Nakamoto; C S Chang; A K Li; G W Chodak
Journal:  Cancer Res       Date:  1992-02-01       Impact factor: 12.701

9.  Basic fibroblast growth factor and its receptor messenger ribonucleic acids are expressed in human ovarian epithelial neoplasms.

Authors:  A M Di Blasio; L Cremonesi; P Viganó; M Ferrari; D Gospodarowicz; M Vignali; R B Jaffe
Journal:  Am J Obstet Gynecol       Date:  1993-12       Impact factor: 8.661

10.  Expression of fibroblast growth factor gene family and its receptor gene family in the human upper gastrointestinal tract.

Authors:  S Iida; O Katoh; A Tokunaga; M Terada
Journal:  Biochem Biophys Res Commun       Date:  1994-03-30       Impact factor: 3.575

View more
  29 in total

1.  New cell lines with chondrocytic phenotypes from human chondrosarcoma.

Authors:  Ikuo Kudawara; Nobuhito Araki; Akira Myoui; Yoichi Kato; Atsumasa Uchida; Hideki Yoshikawa
Journal:  Virchows Arch       Date:  2004-04-29       Impact factor: 4.064

2.  Discriminate gene lists derived from cDNA microarray profiles of limited samples permit distinguishing mesenchymal neoplasia ex vivo.

Authors:  David E Joyner; Mark L Wade; Aniko Szabo; Jeffrey Bastar; Cheryl M Coffin; Karen H Albritton; Philip S Bernard; R Lor Randall
Journal:  J Cancer Res Clin Oncol       Date:  2004-12-22       Impact factor: 4.553

3.  Extracellular sulfatases support cartilage homeostasis by regulating BMP and FGF signaling pathways.

Authors:  Shuhei Otsuki; Sarah R Hanson; Shigeru Miyaki; Shawn P Grogan; Mitsuo Kinoshita; Hiroshi Asahara; Chi-Huey Wong; Martin K Lotz
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

4.  Parallel expression of macrophage metalloelastase (MMP-12) in duodenal and skin lesions of patients with dermatitis herpetiformis.

Authors:  M T Salmela; S L Pender; T Reunala; T MacDonald; U Saarialho-Kere
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

Review 5.  The vitamin D receptor: contemporary genomic approaches reveal new basic and translational insights.

Authors:  J Wesley Pike; Mark B Meyer; Seong-Min Lee; Melda Onal; Nancy A Benkusky
Journal:  J Clin Invest       Date:  2017-02-27       Impact factor: 14.808

6.  Dissection of Wnt5a-Ror2 signaling leading to matrix metalloproteinase (MMP-13) expression.

Authors:  Kaoru Yamagata; Xin Li; Shunkichi Ikegaki; Chitose Oneyama; Masato Okada; Michiru Nishita; Yasuhiro Minami
Journal:  J Biol Chem       Date:  2011-11-28       Impact factor: 5.157

7.  Collagenase 3 is a target of Cbfa1, a transcription factor of the runt gene family involved in bone formation.

Authors:  M J Jiménez; M Balbín; J M López; J Alvarez; T Komori; C López-Otín
Journal:  Mol Cell Biol       Date:  1999-06       Impact factor: 4.272

Review 8.  Biological impact of the fibroblast growth factor family on articular cartilage and intervertebral disc homeostasis.

Authors:  Michael B Ellman; Howard S An; Prasuna Muddasani; Hee-Jeong Im
Journal:  Gene       Date:  2008-05-09       Impact factor: 3.688

9.  siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells.

Authors:  Dae Won Kim; Kyung-Ok Kim; Mike J Shin; Jung Hee Ha; Sung Wook Seo; Jay Yang; Francis Y Lee
Journal:  Mol Cancer       Date:  2009-05-15       Impact factor: 27.401

10.  Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer.

Authors:  M F Leeman; J A McKay; G I Murray
Journal:  J Clin Pathol       Date:  2002-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.